4

Regional hospital September 2011

AA

Regional hospital CT July 20, 2011

Frontotemporal mass (4 × 3.7 cm)

Regional hospital September 15, 2011 Total tumor resection

Regional radiology MRI August 29, 2012

Recurrence

Regional hospital October 26, 2012

GBM

Regional hospital October 25, 2012 Total tumor resection

Regional radiology MRI February 21, 2013 Mass 3.8 × 3.6 cm

Recurrence

BC. February 21, 2013 PB, erlotinib, everolimus, BVZ, pazopanib, TMZ

Discontinued erlotinib after 6 weeks and replaced by dasatinib.

Discontinued dasatinib after 9 months, and everolimus, BVZ and TMZ after 1 year.

Discontinued pazopanib in August 2013 and PB in April 2014.

Regional radiology MRI April 8, 2013

CR

IDH1-R132C mutation, TP53 loss-P190 del, Splice site 672 + 2 T7G, ATRX loss-F395fs19, FBXW7-K189fs66 (tissue)

5

Regional hospital May 20, 2013

GBM

Regional hospital MRI May 2, 2013

Enhancing lesion in corpus callosum and corona radiata

None

Regional radiology MRI May 2, 2013

Left

frontal mass (Baseline)

BC. May 29, 2013 PB, pazopanib, everolimus, lapatinib, BVZ

Regional radiology MRI July 11, 2013

PR

PIK3R1-L380-del, CDKN2A and CDKN2B-Loss, HF1-E318fs*58 mutation (tissue)

6

Regional hospital August 5, 2013

GBM

Regional radiology MRI July 24, 2013

Left temporal-parietal-occipital region tumor

Tumor resection August 5, 2013

RT and TMZ August 28, 2013-September 30, 2013

TMZ 290 mg for 5 days of a 28 day cycle ×6

Regional radiology MRI October 12, 2013

Enhancing lesion 1.2 × 0.9 cm

BC. November 1, 2013 PB, pazopanib, everolimus, dasatinib, erlotinib

Regional radiology MRIs February 19, 2014

SD (post-operative changes)

PTEN-A79T mutation, EGFR-A289D subclonal amplification, EGFRVIII mutation, G598V mutation (subclonal), L62R mutation, CDKN2A/B/C loss (tissue)

7

Regional hospital September 6, 2013

GBM

Regional radiology MRI September 2, 2013

Enhancing left parietal temporal tumor

RT and TMZ September 2013-November 26, 2013

TMZ-December 4, 2013

Regional radiology MRI January 22, 2014

Large enhancing tumor in the left cerebral hemisphere

BC. January 22, 2014 PB, pazopanib, everolimus, dasatinib, BVZ

Regional radiology CT/PET April 24, 2014

PD

PTEN-R130e mutation, CDKN2A/B-loss, VHL-N67M mutation (tissue)

8

Regional medical center

January 27, 2014

GBM

Regional hospital MRI January 25, 2014

Butterfly shaped glioma surrounding the corpus callosum

RT, 30 treatments with TMZ 160 mg daily February 24, 2014- April 4, 2014

TMZ 320 mg, 5 days on and 23 days off May 12, 2014-June 4, 2014

BC. June 6, 2014 PB, dasatinib, everolimus, pazopanib, BVZ.

Discontinued everolimus July 10, 2014. Discontinued treatment July 31, 2014. BVZ August 25, 2014-September 8, 2014 (2×). PB August 25- September 8, 2014. Erlotinib September 10-September 15, 2014

Regional hospital MRI September 3, 2014

SD

VEGF-elevated (blood) EGFR-amplification CDKN2A/B-loss (tissue)